3 doses of mRNA COVID vaccine show advantage against severe outcomes The authors said COVID-19 infection can result in a "brainstem insult" that results in clusters of physical long-COVID symptoms. CIDRAP

A team led by US Food and Drug Administration (FDA) researchers studying Medicare claims data during the early Omicron SARS-CoV-2 variant months conclude that a third dose of mRNA COVID-19 vaccine provides significant protection against hospitalization and death compared with two doses but wanes substantially after 4 months.

...

CDC probes if bird flu mutations impact vaccine stockpile The Centers for Disease Control and Prevention is investigating whether the U.S. stockpile of bird flu vaccines is still well matched to the virus after discovering recent mutations. Medical Xpress

...

Novavax gets EU authorization for updated COVID vaccine targeting JN.1 strain

The European Commission authorized Novavax's (NVAX.O)